Email

i ol ol IH/NIAID) [E] NIH/NIAID) [E] = NIH/NIAID) [E] ay NIH/NIAID) [E] ay VIH/NIAID) [E] iy >; (NIH/NIAID) [E] NIAID) [E] 1S oe 5 AM [AID DEA DART NIAID) [E] i I NIAID) [E] VIH/NIAID) [E] ii NIH/NIAID) [E] J VIH/NIAID) [I] iy >; I I (NIH/NIAID) [E] NIAID) [E] ndences ay > D) (e)] PM [AID DEA DART NIAID) (E] i I \IH/NIAID) [E] ii NIH/NIAID) [E] J co In the attached revised draft, I jections, I will submit these to NIH NIAID) [E] VIH/NIAID) [E] iy >; @niaid.nih.gov>; Harper, Jill (NIH/NIAID) [E] @niaid.nih.gov>; Parker, Marie (NIH/NIAID) [E] @niaid.nih.gov>; Billet, Courtney (NIH/NIAID) [E] @niaid.nih.gov> Cc: NIAID OCGR Leg @mail.nih.gov>; Erbelding, Emily (NIH/NIAID) [E] @nih.gov>; Holland, Steven (NIH/NIAID) [E] @niaid.nih.gov>; Hanson, Christopher (NIH/NIAID) [E] @niaid.nih.gov>; Poe, Kelly (NIH/NIAID) [E] @nih.gov>; Gilles, Sharon (NIH/NIAID) [E] @nih.gov>; DDSM Correspondences @mail.nih.gov> Subject: Additional OSP comments: TA on Risky Research Review Act Hello all, For your awareness, we are providing the attached comments on the Risky Research Review Act from the NIH Office of Science Policy (OSP). We anticipate receiving consolidated NIH comments on the bill, and we will share these as soon as we have them. Please let me know if you have any questions. Thanks, Sara